Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Historical Holders from Q4 2017 to Q3 2025

Symbol
APLS on Nasdaq
CUSIP
03753U106
Type / Class
Equity / Common Stock
Shares outstanding
125M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
132M
Holdings value
$2.28B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
246
Number of buys
147
Number of sells
-116
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MORGAN STANLEY 7.7% $180M 9.59M Morgan Stanley Dec 31, 2024
WELLINGTON MANAGEMENT GROUP LLP 7.2% -23% $156M -$48.9M 9.01M -23.9% Wellington Management Group LLP Jun 30, 2025
Deep Track Capital, LP 5.57% $126M 7M Deep Track Capital, LP May 9, 2025
BlackRock, Inc. 4.5% $105M 5.6M BlackRock, Inc. Mar 31, 2025

Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 230 $5.21K +$3.44K $22.63 1
2025 Q2 132M $2.28B +$66.1M $17.31 246
2025 Q1 126M $2.77B -$78.2M $21.87 251
2024 Q4 127M $4.04B +$259M $31.91 257
2024 Q3 117M $3.38B -$74M $28.84 267
2024 Q2 115M $4.43B +$34.6M $38.36 261
2024 Q1 112M $6.59B -$5.92M $58.78 297
2023 Q4 326K $19.7M +$11.6M $59.86 4
2023 Q3 113M $4.28B -$265M $38.04 247
2023 Q2 105M $9.6B -$396M $91.10 308
2023 Q1 110M $7.27B +$675M $65.96 274
2022 Q4 98.5M $5.09B +$27.4M $51.71 235
2022 Q3 93.9M $6.41B +$1.2M $68.30 239
2022 Q2 91.6M $4.14B +$32.7M $45.22 203
2022 Q1 90.9M $4.62B +$518M $50.81 205
2021 Q4 81M $3.83B +$612M $47.28 182
2021 Q3 68.9M $2.27B -$120M $32.96 171
2021 Q2 64.6M $4.08B +$9.8M $63.20 200
2021 Q1 65M $2.8B +$19.9M $42.91 171
2020 Q4 63.9M $3.65B -$9.73M $57.20 164
2020 Q3 61.7M $1.86B +$25.5M $30.17 140
2020 Q2 61.1M $1.99B +$171M $32.66 138
2020 Q1 54.6M $1.46B +$293M $26.79 142
2019 Q4 43.3M $1.33B +$86.1M $30.62 131
2019 Q3 40.3M $972M +$45.9M $24.09 128
2019 Q2 40.4M $1.02B +$14.3M $25.34 97
2019 Q1 40.1M $782M +$161M $19.50 92
2018 Q4 32M $423M -$27.5M $13.19 93
2018 Q3 29.7M $528M +$9.56M $17.78 78
2018 Q2 29.1M $639M +$267M $22.00 72
2018 Q1 17M $375M +$8.76M $22.11 46
2017 Q4 15.7M $340M +$340M $21.70 46